Evidence map›Paper›PMID 35055081›Full record

ArticleInternational journal of molecular sciences2022

Serum Amyloid A3 Promoter-Driven Luciferase Activity Enables Visualization of Diabetic Kidney Disease.

Tolulope Peter Saliu, Nao Yazawa, Kotaro Hashimoto, Kenshu Miyata, Ayane Kudo, Mayu Horii, Mion Kamesawa, Thanutchaporn Kumrungsee, Noriyuki Yanaka

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tolulope Peter SaliuGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.ORCID 0000-0002-4857-3882
Nao YazawaGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Kotaro HashimotoGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Kenshu MiyataGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Ayane KudoGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Mayu HoriiGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Mion KamesawaGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Thanutchaporn KumrungseeGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.ORCID 0000-0002-6196-5186
Noriyuki YanakaGraduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashi, Hiroshima 739-8528, Japan.
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The early detection of diabetic nephropathy (DN) in mice is necessary for the development of drugs and functional foods. The purpose of this study was to identify genes that are significantly upregulated in the early stage of DN progression and develop a novel model to non-invasively monitor disease progression within living animals using in vivo imaging technology. Streptozotocin (STZ) treatment has been widely used as a DN model; however, it also exhibits direct cytotoxicity to the kidneys. As it is important to distinguish between DN-related and STZ-induced nephropathy, in this study, we compared renal responses induced by the diabetic milieu with two types of STZ models: multiple low-dose STZ injections with a high-fat diet and two moderate-dose STZ injections to induce DN. We found 221 genes whose expression was significantly altered during DN development in both models and identified serum amyloid A3 (

Indexed as

Gene ExpressionGenes, ReporterMolecular ImagingPromoter Regions, GeneticAnimalsBiomarkersDiabetes Mellitus, ExperimentalDiabetic NephropathiesFluorescent Antibody TechniqueGene Expression RegulationInflammation MediatorsLuciferasesLuminescent MeasurementsMiceSerum Amyloid A ProteinTranscriptomeBiomarkersInflammation MediatorsLuciferasesSaa3 protein, mouseSerum Amyloid A Proteindiabetic nephropathyin vivo bioluminescencein vivo imagingserum amyloid A3streptozotocinSTZ-induced diabetic model

Identifiers

PMID35055081
PMCPMC8779903
OpenAlexW4206629264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.